Dr. J. G. Evans, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 669
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of Maryland School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME63658 -
Internal Medicine Physician
FL license ME63658 -
Specialist
FL license ME63658
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- Baptist Medical Center Beaches Jacksonville Beach, FL
- Baptist Medical Center - Nassau Fernandina Beach, FL
- Southeast Georgia Health System -- Camden Campus Saint Marys, GA
- Ed Fraser Memorial Hospital Macclenny, FL
Medical groups
- Northeast Florida Endocrine and Diabetes Associates PA (80 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 669
- Services billed
- 2,940
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 691 | 267 |
| Established patient office or other outpatient visit, 20-29 minutes | 607 | 404 |
| Ultrasound scan of head and neck soft tissue | 202 | 193 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 147 | 62 |
| New patient office or other outpatient visit, 30-44 minutes | 38 | 38 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Jacksonville, FL | 718 |
| Synthroid (levothyroxine sodium) Other prescribers in Jacksonville, FL | 352 |
| Atorvastatin Calcium Other prescribers in Jacksonville, FL | 202 |
| Metformin Hcl Other prescribers in Jacksonville, FL | 199 |
| Ozempic (semaglutide) Other prescribers in Jacksonville, FL | 182 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Jacksonville, FL | 175 |
| Jardiance (empagliflozin) Other prescribers in Jacksonville, FL | 170 |
| Januvia (sitagliptin phosphate) Other prescribers in Jacksonville, FL | 141 |
| Humalog Kwikpen U-100 (insulin lispro) Other prescribers in Jacksonville, FL | 121 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Jacksonville, FL | 119 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 51 payments worth $1,215 in total to this clinician.
| Insulet Corporation | $298 |
|---|---|
| Abbott Laboratories | $257 |
| Beta Bionics, Inc. | $128 |
| Amgen Inc. | $67.83 |
| Ascendis Pharma Endocrinology Inc | $65.28 |
| Novo Nordisk Inc | $61.84 |
| Lilly USA, LLC | $54.54 |
| Corcept Therapeutics | $50.49 |
| Food and Beverage | $1,215 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $358,993 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals Corporation - A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - Study name not reported
Novo Nordisk As - A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
AstraZeneca UK Limited - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.